These dismal effects of IKZF1-mutated AML on CR rate, EFS, RFS, and OS persisted in multivariable analyses adjusting for age, de novo or sAML, and ELN2022 categories (which include monosomy 7 in the adverse risk group) for all outcome variables. This evidence concerns the gene IKZF1 and acute myeloid leukemia.